NONOF NOVO NORDISK A/S
- 128.750
- +1.034+0.81%
NOVO NORDISK A/S News
One in Eight U.S. Adults Admits to GLP-1 Usage as Public Awareness Surges
Novo Nordisk A/S Purchases B Shares Worth DKK 5,428 Million From Novo Holdings A/S Under the 2024 Share Repurchase Programme
Weight-loss Drug Competition Heats Up. Is Wegovy in Trouble?
Novo Nordisk Slides While Moderna Pops: Tale of Two Pharma Stocks
Novo Nordisk Sales up 26% Driven by GLP-1s, Misses 11% on Wegovy
Novo Nordisk CEO on Weight Loss Drugs' 'Exciting Growth Story'
Trending Tickers: Shell, Apple, Novo Nordisk and Standard Chartered
Novo Nordisk GAAP EPADR of DKK 5.68, Revenue of DKK 65.35B; Updates FY24 Outlook
Novo Nordisk's Sales Increased by 22% in Danish Kroner and by 24% at Constant Exchange Rates to DKK 65.3 Billion in the First Three Months of 2024
Apple, Novo Nordisk Earnings, Jobless Claims: What to Watch
Eli Lilly Reports $2 Billion From Mounjaro, Zepbound in Q1 2024
Why These Analysts Are Bullish on Healthcare Stocks
Novo Nordisk A/S – Total Number of Voting Rights and Share Capital in Novo Nordisk A/S as of 26 April 2024
Novo Nordisk A/S – Reduction of the Share Capital
Weight Loss Drugs and the Many Use Cases in Medical Treatments
Eli Lilly Obesity Therapy Succeeds in Late-stage Trials for Sleep Disorder
GLP-1s Benefit Parkinson's: Barclays Sees Implications Across Biopharma
Eliminating the biggest risk of “weight loss elixir”! European Medicines Agency: Drugs such as Wegovy have nothing to do with suicide
On Friday local time, the European Medicines Agency (EMA) announced that after a lengthy review, there is no evidence that GLP-1 drugs such as Novo Nordisk's “weight loss drug” Wegovy increase the risk of suicide or self-harm. Before the US stock market, Novo Nordisk's stock price rose by about 0.7%.
No Link Between Weight Loss Drugs and Suicidal Thoughts, EU Regulator Concludes
Ginkgo Bioworks Expands R&D Tie-up With Novo Nordisk
Analysis
Price Target
No Data
